Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. A consensus statement from the National Lipid Association

Overview of attention for article published in Journal of Clinical Lipidology, May 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (91st percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

Mentioned by

news: 2 news outlets
twitter: 12 X users

guideline: 1 clinical guideline source

Readers on

mendeley: 66 Mendeley

So far, Altmetric has seen 15 X posts from 12 X users, with an upper bound of 60,091 followers.

RT @Pharmaxp: لا حظو أسعار الأدوية .. ومتى تكون Cost-effective ؟ هنا الجواب: Robinson JG, Jayanna MB, Brown AS, et al. Enhancing the value…

لا حظو أسعار الأدوية .. ومتى تكون Cost-effective ؟ هنا الجواب: Robinson JG, Jayanna MB, Brown AS, et al. Enhancing the value of PCSK9 monoclonal antibodies by identifying patients most likely to benefit. J Clin Lipidol https://t.co/VR9ZKFuhIO https://t.co…

RT @quequesierra: Incluso desde una perspectiva de "lipidología", cuando se tienen en cuenta criterios racionales, no hay rastro de un 55 m…

RT @Gustavo22205004: Excelente análisis, debemos buscar el paciente ideal para que los beneficios superen los costos, evitar la inercia ter…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 11 additional X posts.